Background: As the age at first pregnancy continues to rise in the United States so
| INTRODUCTION
Breast cancer is the most common malignancy in women of reproductive age. In 2016, an estimated 246 660 incident cases of breast cancer occurred in the United States, representing 14.6% of all new cancer cases diagnosed in women, and about 40 450 deaths were attributed to this malignancy. 1 As women delay childbearing, the age at first pregnancy continues to increase, resulting in more breast cancers being diagnosed during pregnancy. 2 To date, the majority of pregnancy-associated breast cancer (PABC) research has been limited to examining the impact of pregnancy on breast cancer prognosis. 3 As with any medical condition in pregnancy, it is important to evaluate the perinatal effects of breast cancer for both mother and fetus. A few such studies have been conducted but they were small in size and heterogeneous in nature. [4] [5] [6] [7] [8] The purpose of our study is to evaluate the incidence of PABC and the effect of breast cancer in pregnancy on the fetus using a large population-based cohort of women delivering in the United States.
| MATERIALS AND METHODS
Our study is a population-based cohort study conducted using the All delivery records in the HCUP-NIS data base from 1999 to 2012 were extracted with the delivery-related diagnosis using the ICD-9 codes to create a cohort of patients who delivered during their admission. Then within this cohort, the breast cancer cases in pregnancy were identified using the ICD-9 code for breast cancer (ICD-9-CM 174.9), with the remaining pregnant women without breast cancer composing the comparison group. ICD-9 codes were also used to identify the following outcomes: preterm delivery, preterm premature rupture of membranes (PPROM), intrauterine growth restriction (IUGR), congenital anomalies, and intrauterine fetal demise (IUFD). Note that preterm delivery is defined as the "onset (spontaneous) of delivery before 37 completed weeks of gestation" and "premature labor with onset of delivery, before 37 completed weeks of gestation" (ICD-9 code 644.2). The data in this study were restricted to hospital admissions for deliveries in order to prevent multiple entries for the same patient due to repeat admissions during pregnancy, which would be common for pregnant women with breast cancer.
For the analysis, we first estimated the overall incidence of breast cancer in pregnancy for each year of the dataset. The chisquare test was used to assess the significance of differences in incidence rates over time. Second, the following baseline demographic characteristics of subjects with breast cancer in pregnancy were compared with pregnant women without breast cancer: maternal age, race, median household income, insurance type, hospital location, and smoking history. Finally, multivariate logistic regression models, adjusted for maternal baseline characteristics, examined the effect of breast cancer in pregnancy on perinatal outcomes through the estimation of odds ratios (OR) and 95% confidence intervals (CI).
All statistical analyses were performed using commercially available SAS software (v6.1; SAS Enterprise Guide, Cary, North Carolina).
| RESULTS
Our cohort consisted of 11 846 300 deliveries between 1999 and 2012, of which 772 cases of breast cancer in pregnancy were identified, with an overall incidence of 6.5 cases per 100 000
pregnancies. As shown in Figure 1 , there is a significant increase in the incidence of breast cancer in pregnancy between 1999 and 2012 (P < 0.05), with the incidence reaching 7.5 per 100 000 pregnancies in 2012. Table 1 lists the demographic characteristics of pregnant patients during the study period. As compared with pregnant women without breast cancer, patients with PABC tended to be older, with 49% of them being 35 years of age or older. Furthermore, the women with breast cancer in pregnancy were more likely to be Caucasian, to belong to a higher income quartile, to have private insurance and to be followed in an urban teaching hospital. There was no difference in the percentage of smokers between the groups.
The adjusted pregnancy and fetal outcomes of PABC are presented in Table 2 . Overall, in pregnancies complicated with maternal 
| DISCUSSION
Breast cancer is the most common cancer during the reproductive years, with increasing incidence in the general population over time.
For patients diagnosed with breast cancer during pregnancy, there is a concern not only for their own personal health and prognosis, but also the additional concern for the well-being of their unborn child.
The objectives of our study were to use a large population-based cohort to evaluate the incidence of breast cancer in pregnancy over time and determine its effects on newborn outcomes. Our results suggest that breast cancer in pregnancy is becoming an ever increasingly relevant health issue as there has been a significant upward trend in its incidence between 1999 and 2012. We found significant higher risk for preterm delivery and PPROM among the PABC group.
However, the effect of breast cancer on the fetus was found to be nonsignificant for fetal malformations and fetal growth restriction.
Overall, the incidence of breast cancer is rare but it is the most common cancer in pregnant and postpartum women, occurring in 1 in 3000 pregnancies. 9, 10 The incidence of PABC was considerably varied based on the population that was evaluated in previous studies. 2, 11, 12 The variations can be explained partially by the definition of the term PABC and the inclusion criteria used. Specifically, some studies included only breast cancers diagnosed during pregnancy, while others also included breast cancers diagnosed in the first year postpartum. Our study specifically restricted its focus to breast cancers diagnosed during pregnancy, not the postpartum, as our objective was to examine the effect of breast cancer on fetal/newborn outcomes. Our findings of an upward temporal trend in PABC incidence and the fact that pregnant patients of more advanced age were at greater risk of breast cancer underscores the necessity of examining the impact of this disease on the fetus and the fetal complications in pregnancy.
We found some demographic differences between women who had breast cancer during pregnancy and those who did not. Women with PABC in our study were comparatively older than those without breast cancer. This association has been reported previously 12 and it is well established that the risk for breast cancer increases with maternal age. 13 We found that Caucasian ethnicity was more common in the PABC group, which might represent an early detection in this population, as described in a previous study, 14 or it may reflect a true difference in the risk patterns of this disease. 15, 16 The patients diagnosed with PABC were more likely to possess private Adjusted for all baseline characteristics inTable 1 health insurance and to be in a higher income quartile, which may both indicate achievement of higher education levels. Hence, allowing for greater accessibility to the medical system due to a greater personal knowledge or to closer medical follow-up. 12 Furthermore, greater income may reflect possession of a higher status occupation, better access to healthcare and perhaps, a greater likelihood to be diagnosed with PABC. 17 Patients with PABC were treated more often in an urban teaching hospital, which is probably biased due to the referral of these patients to a more central, tertiary care center because of the seriousness of the circumstances.
It is important to consider chemotherapy in studies examining fetal outcomes of breast cancer during pregnancy due to the fact that chemotherapeutic agents can cross the placenta, thus, exposing the fetus to toxic drugs that are potentially teratogenic. Although some of the chemotherapy drugs are known to be cardio-toxic to the mother, when evaluating the fetus for cardiac findings, the findings were normal. 18, 19 Also, the latest publications did not find longterm cognitive adverse effects in babies that were exposed to chemotherapy when compared with those who were not. [18] [19] [20] Several studies have shown that chemotherapy given to breast cancer patients during pregnancy resulted in malformation rates not greater than that in the general population. 5, 6, 8, 20 Treatment information was not available in the HCUP-NIS data base; hence, we could not differentiate between patients who received or did not receive chemotherapy and/or surgery during pregnancy and as a result, we
were not able to evaluate their direct effects on fetal outcomes in the PABC group. Nevertheless, given that breast cancer treatment is advised to not be delayed on account of pregnancy, it is not unlikely that women with PABC received treatment in the form of surgery and/or chemotherapy while pregnant. As such, our findings that suggest no increase in IUGR and congenital malformations in the PABC group are reassuring particularly since many women with PABC do receive treatments during pregnancy.
Preterm births have been previously associated with breast cancer during pregnancy, which is consistent with our findings.
19
A study by Loibl et al evaluated whether this increased risk of preterm births may be associated with the breast cancer treatments received. They found that prematurity was not related to the use of chemotherapy during pregnancy, although they appeared to underestimate the rate of preterm delivery, which may be attributed to the small sample size of their study. 7 Alternatively, the increased risk for preterm delivery among the PABC group in our study might not reflect a direct effect of treatment itself but rather, may stem from the cancer itself or it may be an iatrogenic effect of preterm induction of labor and delivery in order to allow for more aggressive treatment of the cancer postpartum. Moreover, the greater likelihood of PPROM in the PABC group in our study may also contribute to the increased rate of preterm deliveries. Unfortunately, our data source does not contain information regarding the specific treatments received for breast cancer during pregnancy, the timing of the treatments, or other specific details surrounding premature births so we were unable to examine the possible links with premature birth. It is important for future studies to explore the underlying reasons for the association between preterm births in the context of pregnancies complicated with breast cancer.
The limitations of our study are due to us using an administrative data base that contains data not specifically collected for our study.
We cannot distinguish patients by the treatment received during pregnancy and evaluate how these may lead to different fetal outcomes. Furthermore, we do not have data regarding terminations, only pregnancies ending with deliveries; therefore, it is plausible that we may have underestimated the incidence of fetal malformations and severe early fetal growth restriction in the PABC group.
The main strength of our study is its sample size since, to our knowledge, this study is the largest to date to have evaluated the effect of breast cancer in pregnancy on the fetus. The availability of vast demographic and clinical data allowed for the control of potential confounding. In addition, the population is homogenous in the sense that it is limited to the United States where protocols and treatments for women with breast cancer during pregnancy are standard across populations. Lastly, the diagnostic and procedural codes used were uniform.
| CONCLUSION
Our study showed there is an increasing incidence of breast cancer in pregnancy; and therefore, the need for counseling these patients about their fetus' prognosis is also increasing. Although pregnancies with the diagnosis of maternal breast cancer might be delivered earlier, the babies are not at increased risk for IUGR, anomalies, or IUFD, which are reassuring findings for the mothers.
CONFLI CT OF INTEREST
The authors report no conflict of interest.
O R C I D
Haim Arie Abenhaim http://orcid.org/0000-0002-7001-7153
